MYC and Miyoshi myopathy: The high intracellular S1P level inactivates PP2A through prevention of ceramide competitive interference with the binding of the I2PP2A inhibitor, and thus stabilizes c-Myc expression in MM cells to increase their survival (Figure 2B).